Sitagliptin for Reducing Inflammation and Immune Activation
Status:
Completed
Trial end date:
2017-01-10
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate whether sitagliptin (Januvia is the brand name for
sitagliptin) reduces inflammation and immune activation markers in HIV-infected men and women
when compared to a placebo (inactive medication like a dummy pill). The study evaluated
whether taking 100 mg of sitagliptin by mouth daily for 16 weeks is safe and effective for
HIV-infected persons on antiretroviral therapy (ART) who do not have diabetes. Sitagliptin is
a medication that is used to treat people with diabetes (high blood sugar) but also may
reduce inflammation in the body.
Phase:
Phase 2
Details
Lead Sponsor:
AIDS Clinical Trials Group
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)
Treatments:
Dipeptidyl-Peptidase IV Inhibitors Sitagliptin Phosphate